The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells
- PMID: 22771084
- DOI: 10.1016/j.ultras.2012.06.005
The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells
Abstract
We aimed to investigate the role of the ABCG2 transporter in the efficacy of sonodynamic therapy (SDT) with Photofrin in the glioma stem-like cells (GSCs) isolated and cultured from U251 glioma cells. Immunocytochemistry and flow cytometry analyses showed that ABCG2 was overexpressed in GSCs, and the percentage of ABCG2-positive GSCs was approximately 100%. The effect of ABCG2 on Photofrin extrusion in the absence or presence of a specific inhibitor of ABCG2 (fumitremorgin C; FTC) was investigated by determining the intracellular concentration of Photofrin in GSCs incubated with 20μg/ml Photofrin. Extrusion of Photofrin by ABCG2 was inhibited by 10μM FTC, which significantly increased the intracellular Photofrin concentration (p<0.05) from 0.32±0.11μg/10(6) cells to 0.89±0.13μg/10(6) cells. MTT and TUNEL assays showed that the antitumor effect of SDT (incubation of GSCs with 20μg/ml Photofrin for 6h in the dark and ultrasonic activation at 1.0MHz and 0.5W/cm(2) for 2min) was significantly improved by FTC pretreatment (p<0.05). Moreover, incubation of GSCs with FTC significantly increased the relative production of ROS in response to SDT. The overexpression of ABCG2 in GSCs results in efflux of Photofrin, indicating that the antitumor effect of SDT with Photofrin may be reduced in GSCs overexpressing ABCG2. However, since FTC improves the efficacy of SDT in GSCs by inhibiting ABCG2-mediated efflux of Photofrin, FTC may be useful in SDT treatment of ABCG2-expressing cancer cells.
Crown Copyright © 2012. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Sonodynamic Therapy and Sonosensitizers for Glioma Treatment: A Systematic Qualitative Review.World Neurosurg. 2023 Oct;178:60-68. doi: 10.1016/j.wneu.2023.07.030. Epub 2023 Jul 15. World Neurosurg. 2023. PMID: 37454909 Review.
-
Sonodynamic therapy for gliomas.J Neurooncol. 2022 Jan;156(1):1-10. doi: 10.1007/s11060-021-03807-6. Epub 2021 Jul 12. J Neurooncol. 2022. PMID: 34251601 Review.
-
Glioma stem-like cells are less susceptible than glioma cells to sonodynamic therapy with photofrin.Technol Cancer Res Treat. 2012 Dec;11(6):615-23. doi: 10.7785/tcrt.2012.500277. Epub 2012 Jul 10. Technol Cancer Res Treat. 2012. PMID: 22775340
-
Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.Lung Cancer. 2010 Feb;67(2):198-204. doi: 10.1016/j.lungcan.2009.04.002. Epub 2009 May 23. Lung Cancer. 2010. PMID: 19477032
-
In vitro study of haematoporphyrin monomethyl ether-mediated sonodynamic effects on C6 glioma cells.Neurol Sci. 2008 Sep;29(4):229-35. doi: 10.1007/s10072-008-0972-8. Epub 2008 Sep 20. Neurol Sci. 2008. PMID: 18810596
Cited by
-
Curcumin-Triterpene Type Hybrid as Effective Sonosensitizers for Sonodynamic Therapy in Oral Squamous Cell Carcinoma.Pharmaceutics. 2023 Jul 23;15(7):2008. doi: 10.3390/pharmaceutics15072008. Pharmaceutics. 2023. PMID: 37514194 Free PMC article.
-
Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier.Cancers (Basel). 2022 Oct 8;14(19):4920. doi: 10.3390/cancers14194920. Cancers (Basel). 2022. PMID: 36230843 Free PMC article. Review.
-
Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives.Mil Med Res. 2022 Jun 9;9(1):26. doi: 10.1186/s40779-022-00386-z. Mil Med Res. 2022. PMID: 35676737 Free PMC article. Review.
-
Sonodynamic therapy induces oxidative stress, DNA damage and apoptosis in glioma cells.RSC Adv. 2018 Oct 25;8(63):36245-36256. doi: 10.1039/c8ra07099g. eCollection 2018 Oct 22. RSC Adv. 2018. PMID: 35558463 Free PMC article.
-
Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives.Cancers (Basel). 2022 Apr 15;14(8):2004. doi: 10.3390/cancers14082004. Cancers (Basel). 2022. PMID: 35454910 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical